Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Regulus Therapeutics (Nasdaq: RGLS), a biopharmaceutical company specializing in microRNA-targeted medicine development, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, February 11th at 2:40 p.m. ET.
Investors and interested parties can access both the live event and replay through the investor relations section of Regulus' website at https://ir.regulusrx.com/events. The presentation recording will remain accessible for 90 days following the event.
Regulus Therapeutics (Nasdaq: RGLS), un'azienda biofarmaceutica specializzata nello sviluppo di medicine mirate al microRNA, ha annunciato la sua partecipazione alla 35a Conferenza Annuale Oppenheimer sulle Scienze della Vita e della Salute. Il team di gestione dell'azienda prenderà parte a una conversazione informale programmata per martedì 11 febbraio alle 14:40 ET.
Investitori e parti interessate possono accedere sia all'evento dal vivo che alla registrazione successiva tramite la sezione delle relazioni con gli investitori del sito web di Regulus all'indirizzo https://ir.regulusrx.com/events. La registrazione della presentazione rimarrà accessibile per 90 giorni dopo l'evento.
Regulus Therapeutics (Nasdaq: RGLS), una compañía biofarmacéutica especializada en el desarrollo de medicamentos dirigidos al microRNA, ha anunciado su participación en la 35ª Conferencia Anual Oppenheimer de Ciencias de la Vida y de la Salud. El equipo de gestión de la compañía participará en una charla informal programada para el martes 11 de febrero a las 2:40 p.m. ET.
Los inversores y partes interesadas pueden acceder tanto al evento en vivo como a la repetición a través de la sección de relaciones con inversores del sitio web de Regulus en https://ir.regulusrx.com/events. La grabación de la presentación permanecerá accesible por 90 días después del evento.
Regulus Therapeutics (Nasdaq: RGLS)는 마이크로RNA 표적 의약품 개발을 전문으로 하는 생명공학 회사로서 오펜하이머 제35회 연례 헬스케어 생명과학 회의에 참여한다고 발표했습니다. 회사의 경영진은 2월 11일 화요일 오후 2시 40분 ET에 예정된 포럼에 참석할 예정입니다.
투자자 및 관심 있는 분들은 Regulus의 웹사이트 https://ir.regulusrx.com/events의 투자자 관계 섹션을 통해 라이브 이벤트와 재생을 모두 접근할 수 있습니다. 발표 녹화는 90일 동안 이벤트 후에도 계속해서 열람할 수 있습니다.
Regulus Therapeutics (Nasdaq: RGLS), une entreprise biopharmaceutique spécialisée dans le développement de médicaments ciblant les microARN, a annoncé sa participation à la 35ème Conférence Annuelle Oppenheimer sur les Sciences de la Vie et de la Santé. L'équipe de direction de la société participera à un chat informel prévu pour mardi 11 février à 14h40 ET.
Les investisseurs et les parties intéressées peuvent accéder à la fois à l'événement en direct et à la rediffusion via la section des relations avec les investisseurs du site web de Regulus à l'adresse https://ir.regulusrx.com/events. L'enregistrement de la présentation restera accessible pendant 90 jours après l'événement.
Regulus Therapeutics (Nasdaq: RGLS), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von mikroRNA-gezielten Arzneimitteln spezialisiert hat, hat seine Teilnahme an der 35. jährlichen Oppenheimer-Konferenz für Lebenswissenschaften im Gesundheitswesen angekündigt. Das Managementteam des Unternehmens wird an einem informellen Gespräch teilnehmen, das für Dienstag, den 11. Februar um 14:40 Uhr ET angesetzt ist.
Investoren und interessierte Parteien können sowohl auf die Live-Veranstaltung als auch auf die Wiederholung über den Bereich der Investorenbeziehungen auf der Website von Regulus unter https://ir.regulusrx.com/events zugreifen. Die Präsentationsaufzeichnung bleibt für 90 Tage nach der Veranstaltung zugänglich.
- None.
- None.
The live event and replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in
View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-302366886.html
SOURCE Regulus Therapeutics Inc.
FAQ
When is Regulus Therapeutics (RGLS) presenting at the Oppenheimer Healthcare Conference?
How long will the RGLS Oppenheimer Conference presentation replay be available?
Where can investors watch Regulus Therapeutics' (RGLS) Oppenheimer Conference presentation?
What type of presentation will RGLS give at the Oppenheimer Healthcare Conference?
